Literature DB >> 2685093

Injection sites and pharmacokinetics of luteinizing hormone releasing hormone: comparison of two different subcutaneous administration routes.

R Torre1, L Traverso, P Cavagnaro, M Giusti, G Giordano.   

Abstract

A normal pituitary-gonadal function is reinduced by iv or sc pulsatile LHRH therapy, administered by a portable pump. In order to evaluate the differences between different sites of injection on the LHRH bioavailability, we compared the LHRH plasma concentration after a single LHRH injection in the lower abdominal wall and in the upper arm, in 5 patients with idiopathic hypogonadotropic hypogonadism, during LHRH treatment. Our data showed no significant differences in using both administration routes. In fact, LHRH absorption (secretory area and peak value) is quite similar. However, patients tolerated LHRH administration in the abdominal wall more so than in the upper arm. Both ways of administration are effective with regards to the pituitary responsiveness but we can not forget that patients compliance is of great importance in order to obtain the best results in a long-term therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2685093     DOI: 10.1007/bf03350012

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  12 in total

1.  The spectrum of abnormal patterns of gonadotropin-releasing hormone secretion in men with idiopathic hypogonadotropic hypogonadism: clinical and laboratory correlations.

Authors:  D I Spratt; D B Carr; G R Merriam; R E Scully; P N Rao; W F Crowley
Journal:  J Clin Endocrinol Metab       Date:  1987-02       Impact factor: 5.958

Review 2.  Gonadotrophin releasing hormone: from physiology to pharmacology.

Authors:  R N Clayton
Journal:  Clin Endocrinol (Oxf)       Date:  1987-03       Impact factor: 3.478

3.  Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone.

Authors:  P E Belchetz; T M Plant; Y Nakai; E J Keogh; E Knobil
Journal:  Science       Date:  1978-11-10       Impact factor: 47.728

4.  Pulsatile subcutaneous low-dose gonadotropin-releasing hormone treatment of anovulatory infertility.

Authors:  G Skarin; S J Nillius; L Wide
Journal:  Fertil Steril       Date:  1983-10       Impact factor: 7.329

5.  Participation of endogenous opiates in regulation of the hypothalamic-pituitary-testicular axis in normal men.

Authors:  G Delitala; M Giusti; G Mazzocchi; L Granziera; W Tarditi; G Giordano
Journal:  J Clin Endocrinol Metab       Date:  1983-12       Impact factor: 5.958

6.  Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone.

Authors:  A R Hoffman; W F Crowley
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

7.  Events surrounding the initiation of puberty with long term subcutaneous pulsatile gonadotropin-releasing hormone in a female patient with Kallman's syndrome.

Authors:  M M Seibel; P Claman; S P Oskowitz; C McArdle; F G Weinstein
Journal:  J Clin Endocrinol Metab       Date:  1985-09       Impact factor: 5.958

8.  Effect of injection site on the pharmacokinetics and pharmacodynamics of subcutaneously administered luteinizing hormone releasing hormone.

Authors:  S M Blunt; R N Clayton; W R Butt
Journal:  Clin Endocrinol (Oxf)       Date:  1986-11       Impact factor: 3.478

Review 9.  The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women.

Authors:  W F Crowley; M Filicori; D I Spratt; N F Santoro
Journal:  Recent Prog Horm Res       Date:  1985

10.  Hypogonadotropic hypogonadism: hormonal responses to low dose pulsatile administration of gonadotropin-releasing hormone.

Authors:  T W Valk; K P Corley; R P Kelch; J C Marshall
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

View more
  1 in total

Review 1.  Update on pulsatile luteinizing hormone-releasing hormone therapy in males with idiopathic hypogonadotropic hypogonadism and delayed puberty.

Authors:  M Giusti; P Cavagnaro
Journal:  J Endocrinol Invest       Date:  1991-05       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.